The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation-Reference-Cited by-同舟云学术

The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation

Published:2010-03-03 Issue:6 Volume:87 Page:1083-1095
ISSN:0741-5400
Container-title:Journal of Leukocyte Biology
language:en
Short-container-title:Journal of Leukocyte Biology

Author:

Beer-Hammer Sandra,Zebedin Eva,von Holleben Max,Alferink Judith,Reis Bernhard,Dresing Philipp,Degrandi Daniel,Scheu Stefanie,Hirsch Emilio,Sexl Veronika,Pfeffer Klaus,Nürnberg Bernd,Piekorz Roland P.

Funder

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Cell Biology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1189/jlb.0809585/fullpdf

Reference49 articles.

1. PI3K in lymphocyte development, differentiation and activation;Okkenhaug;Nat. Rev. Immunol.,2003

2. Phospholipid kinases;Nürnberg,2008

3. Roles of non-catalytic subunits in Gβy-induced activation of class I phosphoinositide 3-kinase isoforms β and γ;Maier;J. Biol. Chem.,1999

4. Class I PI3K in oncogenic cellular transformation;Zhao;Oncogene,2008

5. Roles of Gβγ in membrane recruitment and activation of p110 y/p101 phosphoinositide 3-kinase γ;Brock;J. CellBiol.,2003

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PI3Kγ in B cells promotes antibody responses and generation of antibody-secreting cells;Nature Immunology;2024-07-03

2. Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies;Frontiers in Pharmacology;2024-06-14

3. FDA approved fused-pyrimidines as potential PI3K inhibitors: a computational repurposing approach;Journal of Biomolecular Structure and Dynamics;2023-11

4. Extranodal lymphoma: pathogenesis, diagnosis and treatment;Molecular Biomedicine;2023-09-18

5. High expression of the phosphoinositide 3-kinase p110γ isoform can predict poor prognosis of non-small cell lung cancer;HISTOL HISTOPATHOL;2022